Protagenic Therapeutics, Inc. ew (OTC:PTIX)
| Market Cap | 1.58M-73.8% |
| Revenue (ttm) | 0+100.0% |
| Net Income | 5.46M+162.8% |
| EPS | 2.95+165.6% |
| Shares Out | 1.81M |
| PE Ratio | 0.30 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Dec 5, 2005 |
| Volume | 300 |
| Open | 0.81 |
| Previous Close | 0.87 |
| Day's Range | 0.81 - 0.87 |
| 52-Week Range | 0.13 - 4.55 |
| Beta | 1.07 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 17, 2026 |
About PTIX
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$PTIX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in PTIX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PTIX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PTIX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New PTIX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PTIX from public contracts
Source: USAspending.gov
PTIX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from PTIX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score